Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) Sees Large Increase in Short Interest

Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) (TSE:CPH) was the target of a significant increase in short interest in February. As of February 28th, there was short interest totalling 136,200 shares, an increase of 20.4% from the February 13th total of 113,100 shares. Based on an average trading volume of 39,400 shares, the short-interest ratio is presently 3.5 days.

Cipher Pharmaceuticals Trading Up 12.7 %

Shares of OTCMKTS CPHRF opened at $9.43 on Thursday. The business’s fifty day simple moving average is $9.01 and its 200-day simple moving average is $10.35. Cipher Pharmaceuticals has a 12-month low of $5.62 and a 12-month high of $14.60.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.